Particulate and drug-induced toxicity assessed in novel quadruple cell human primary hepatic disease models of steatosis and pre-fibrotic NASH.
Authors
Kermanizadeh, AliValli, Jessica
Sanchez, Katarzyna
Hutter, Simon
Pawlowska, Agnieszka
Whyte, Graeme
Moritz, Wolfgang
Stone, Vicki
Affiliation
University of DerbyHeriot Watt University, Edinburgh
InSphero AG, Wagistrasse 27a, Schlieren, Switzerland
Issue Date
2021-10-20
Metadata
Show full item recordAbstract
In an effort to replace, reduce and refine animal experimentation, there is an unmet need to advance current in vitro models that offer features with physiological relevance and enhanced predictivity of in vivo toxicological output. Hepatic toxicology is key following chemical, drug and nanomaterials (NMs) exposure, as the liver is vital in metabolic detoxification of chemicals as well as being a major site of xenobiotic accumulation (i.e., low solubility particulates). With the ever-increasing production of NMs, there is a necessity to evaluate the probability of consequential adverse effects, not only in health but also in clinically asymptomatic liver, as part of risk stratification strategies. In this study, two unique disease initiation and maintenance protocols were developed and utilised to mimic steatosis and pre-fibrotic NASH in scaffold-free 3D liver microtissues (MT) composed of primary human hepatocytes, hepatic stellate cells, Kupffer cells and sinusoidal endothelial cells. The characterized diseased MT were utilized for the toxicological assessment of a panel of xenobiotics. Highlights from the study included: 1. Clear experimental evidence for the pre-existing liver disease is important in the augmentation of xenobiotic-induced hepatotoxicity and 2. NMs are able to activate stellate cells. The data demonstrated that pre-existing disease is vital in the intensification of xenobiotic-induced liver damage. Therefore, it is imperative that all stages of the wide spectrum of liver disease are incorporated in risk assessment strategies. This is of significant consequence, as a substantial number of the general population suffer from sub-clinical liver injury without any apparent or diagnosed manifestations.Citation
Kermanizadeh, A., Valli, J., Sanchez, K., Hutter, S., Pawlowska, A., Whyte, G., Moritz, W. and Stone, V. (2021). 'Particulate and drug-induced toxicity assessed in novel quadruple cell human primary hepatic disease models of steatosis and pre-fibrotic NASH'. Archives of toxicology, 96(1), pp. 287-303.Publisher
SpringerJournal
Archives of toxicologyDOI
10.1007/s00204-021-03181-2PubMed ID
34668024Additional Links
https://link.springer.com/article/10.1007/s00204-021-03181-2Type
ArticleLanguage
enEISSN
1432-0738ae974a485f413a2113503eed53cd6c53
10.1007/s00204-021-03181-2
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Related articles
- Assessment of nanomaterial-induced hepatotoxicity using a 3D human primary multi-cellular microtissue exposed repeatedly over 21 days - the suitability of the in vitro system as an in vivo surrogate.
- Authors: Kermanizadeh A, Berthing T, Guzniczak E, Wheeldon M, Whyte G, Vogel U, Moritz W, Stone V
- Issue date: 2019 Nov 19
- Cooperation of liver cells in health and disease.
- Authors: Kmieć Z
- Issue date: 2001
- A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates.
- Authors: Ströbel S, Kostadinova R, Fiaschetti-Egli K, Rupp J, Bieri M, Pawlowska A, Busler D, Hofstetter T, Sanchez K, Grepper S, Thoma E
- Issue date: 2021 Nov 23
- A review of hepatic nanotoxicology - summation of recent findings and considerations for the next generation of study designs.
- Authors: Kermanizadeh A, Powell LG, Stone V
- Issue date: 2020 May 18
- Hepatic toxicology following single and multiple exposure of engineered nanomaterials utilising a novel primary human 3D liver microtissue model.
- Authors: Kermanizadeh A, Løhr M, Roursgaard M, Messner S, Gunness P, Kelm JM, Møller P, Stone V, Loft S
- Issue date: 2014 Oct 20